It should be noted that HDAC inhibitors have illustrated anticancer properties (Bojang and Ramos, 2014), with high HDAC2 expression correlating with increased aggression in esophageal cancer (Langer et al., 2010). Here, HDAC9 is linked to esophageal cancer.